日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.

一项 I 期研究,旨在评估膀胱内注射靶向 EpCAM 的免疫毒素治疗 BCG 难治性或 BCG 不耐受患者的非肌层浸润性膀胱癌的疗效

Kowalski Mark, Entwistle Joycelyn, Cizeau Jeannick, Niforos Demi, Loewen Shauna, Chapman Wendy, MacDonald Glen C

A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

VB4-845 的 I 期临床研究:每周对头颈部鳞状细胞癌患者进行瘤内注射抗 EpCAM 重组融合蛋白

MacDonald Glen C, Rasamoelisolo Michèle, Entwistle Joycelyn, Cizeau Jeannick, Bosc Denis, Cuthbert Wendy, Kowalski Mark, Spearman Maureen, Glover Nick

StARD13(Dlc-2) RhoGap mediates ceramide activation of phosphatidylglycerolphosphate synthase and drug response in Chinese hamster ovary cells

StARD13(Dlc-2) RhoGap介导神经酰胺激活磷脂酰甘油磷酸合成酶,并影响中国仓鼠卵巢细胞的药物反应。

Hatch, Grant M; Gu, Yuan; Xu, Fred Y; Cizeau, Jeannick; Neumann, Shannon; Park, Ji-Seon; Loewen, Shauna; Mowat, Michael R A